CEO buying at Knight Therapeutics (GUD)

CEO buying at Knight Therapeutics (T:GUD)

Jonathan Goodman, CEO, Director and 10% Holder, acquired 17,800 Common Shares on a direct ownership basis at a price of $7.370 on May 15th, 2019. This represents a $131,186 investment into the company's shares and an account share holdings change of 3.9%.

Knight Therapeutics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm. Knight Therapeutics Inc. (GUD) has a high amount of executive buying compared to its mid-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $131,186.